A double-blind, randomized, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending oral doses of ASP2905 in healthy young males, including an open-label two-period randomized crossover study to compare the pharmacokinetics under fasted and fed conditions
Completed
- Conditions
- ziekte van Alzheimer, schizofrenieAlzheimer's Disease and schizophreny
- Registration Number
- NL-OMON32022
- Lead Sponsor
- Astellas Pharma
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 68
Inclusion Criteria
- Healthy young male subject, aged 18-50 years inclusive.
Exclusion Criteria
current clinically significant diseases or conditions or any clinical significant diseases or conditions in medical history.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>nvt</p><br>
- Secondary Outcome Measures
Name Time Method <p>nvt</p><br>